This article describes the numerous activities in the commercial quality control (QC) network that aim to replace in vivo assays with alternative methods in the course of production and release.1
Reducing the pharmaceutical industry’s carbon footprint has become a management responsibility. This article introduces some of the key points, actual methods, and practical examples of our implementation to reduce carbon emissions from pharmaceutical manufacturing facilities in Southeast Asia.
The decision to pursue net-zero facility design in manufacturing is complicated. There are significant challenges related to initial project costs, physical space constraints, and project site considerations—but also substantive benefits from operational savings, environmental impact, building brand trust, and working toward a more sustainable future.
Single-use products used in the production of biologics provide flexibility that was unimaginable a few years ago. The implementation of single-use technology (SUT) in manufacturing operations has accelerated due to reduced risk, flexible process equipment adjustments, and lower capital cost. The widespread use of this technology has raised questions about its impact on the environment due to...
Traditionally, a regulated company is accountable for all aspects of their infrastructure qualification and application validation. With the introduction of public cloud service providers (CSPs), part of that technical responsibility has shifted to a cloud supplier, making supplier assessment and supplier management more important than ever—even though the regulated company is still...
For more than 22 years, James P. Wabby has dedicated his career to quality operations, regulatory compliance, and regulatory affairs pertaining to medical device technology, medicinal delivery platforms, complex generics, companion diagnostics, digital medicine, and combination product areas. In 2017, during one of the biggest regulatory changes within the European Union in over 20 years,...
Ester Lovsin Barle’s journey from veterinary lecturer in Slovenia to the Global Head of Product Sustainability and Stewardship at Takeda Pharmaceuticals in Switzerland was fueled by her curiosity and passion for continual learning and a desire to help others do the same. “We are never at the end of our learning curve, and it’s so important to continue to learn and be open-minded about new...
Established in 2004, the Facility of the Year Awards (FOYA) recognize state-of-the-art projects utilizing new, innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery.
The 2024 ISPE Pharma 4.0™ and Annex 1 Conference will be held 10–11 December in Rome, Italy, and virtually. Richard Denk and Line Lundsberg-Nielsen, the conference’s Executive Chairs, offer advice...
Pharmaceutical and biotechnology companies employ platform analytical procedures in the development stages of their synthetic and biological drug products and are beginning to leverage them for commercial products. This shift is supported by the acceptance of platform procedures in the recently adopted ICH Q2(R2) and ICH Q14. Six case studies are shared in this article to highlight how...
The pharmaceutical industry faces considerable challenges throughout the development, manufacturing, and supply of medicines, largely due to the intricate and divergent global regulatory landscape. The adoption of structured data standards and utilization of cloud-based platforms offer immense potential to overcome these challenges by facilitating faster and more efficient global...
On 13 March 2024, ISPE concluded the 2024 Aseptic Conference with a regulatory panel question and answer session. Attendees were invited to submit questions to representatives from the Austrian Agency for Health and Food Safety (AGES), US Food and Drug Administration (FDA), Regierungspraesidium Tübingen (RP Tübingen), World Health Organization (WHO), Therapeutic Goods Administration (TGA), and...
The pharmaceutical industry stands at the precipice of a revolution as emerging digital technologies provide new opportunities to boost productivity through continuous process improvements. The Pharma 4.0™ framework, an adaptation of the broader Industry 4.0 movement, aims to transform how drugs are produced and delivered.
With the approval of the first gene edited therapeutic in 2023, production of gene edited therapies is accelerating, introducing tough decisions for manufacturing development. Gene editing therapy production is complex, often involving multi-modality manufacturing operations in one facility to produce a single therapeutic. This article considers whether retrofitting an aging monoclonal...
Implementing advanced automation technologies is a strategic move that can amplify the positive outcomes of environmental, social, and governance (ESG) initiatives. By leveraging ESG initiatives, pharmaceutical companies can enhance their competitive edge and contribute positively to global sustainability efforts.
Cell and gene therapy (C>) products represent a significant step forward in patient treatment and often offer unique patient benefits. However, product developers face significant hurdles within the regulatory landscape. The tools laid out in the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q12 guideline: “Technical and...
The US Food and Drug Administration (FDA) advocates for the integration of quality by design (QbD) principles throughout the pharmaceutical product development landscape, aiming to elevate both process understanding and product quality. Key challenges to the process control strategy include navigating time- and resource-intensive processes. One solution is digital shadow technology which, when...
In the dynamic and highly regulated world of biopharmaceutical manufacturing, maintaining and ensuring quality is a critical success factor. An effective quality risk management (QRM) system is a key component in the overall quality management infrastructure of biopharmaceutical organizations. It offers a structured, scientific, and risk-based approach to decision-making, addressing potential...
Advanced therapy medicinal products (ATMPs) and cell and gene therapies (C>s) represent a promising medical product class that employs gene therapy, cell therapy, or tissue engineering to address various diseases and injuries. One critical aspect of ATMP and C> manufacturing is using cell culture media. With thousands of ATMPs and C>s in clinical trial phases, the role of...
Antibody engineering has transformed the development of therapeutic antibodies, enabling the creation of specific and effective treatments for a range of diseases. These antibody-based therapeutics are advancing in clinical development at a rapid rate and are being approved in record numbers. Currently, more than 100 monoclonal antibodies (mAbs) have been approved for the treatment of various...
Although traditional tank farm systems have long been the cornerstone of buffer preparation, they face challenges that have grown with the expansion of processing scale in the industry.
With the Chinese government initiating drug regulatory reform in 2015 and China joining the International Council for Harmonisation (ICH) in 2017, a significant number of measures have been implemented by the government. The aim is to make fundamental changes to China’s drug regulatory administration system so it can facilitate pharmaceutical development and better meet patient needs in the...
Digital display labels (DDLs) offer an alternative solution to eliminate manual relabeling in the clinical supply chain, optimizing label content updates through a simple, system-controlled approach while providing new, uncharted opportunities. With increased efficiency in making regulatory-compliant changes and enhanced flexibility in the clinical supply chain, DDL technology has the...
Due to the growing digitalization of the industry, we are highly dependent on information technology (IT) systems and data. The basic ability to execute our pharmaceutical business and decision-making processes relies on the permanent availability of these IT systems and data to ensure compliance and efficiency of our business operations. But numerous factors—including criminal activities,...
Faced with global competition and shrinking margins, (bio)pharmaceutical manufacturers worldwide are urged to increase production efficiency by making better use of time and resources. This is in addition to addressing the unique challenges faced by pharmaceutical manufacturers such as a strictly regulated environment, heterogeneous equipment suppliers, and long adaptation times....
This Concept Paper proves that a standard model within OPC UA Alarms and Conditions (OPC UA Part 9) can be leveraged to realize Plug & Produce for exchanging pharmaceutical alarms and audit trails between OT manufacturing equipment and Orchestration Platforms or IT Services like EBR or Historian.
This Concept Paper proves a laboratory device integration utilizing the Asset Administration Shell (AAS) metamodel (agnostic to the underlying technology and data structure).
In an increasingly complex world, where the reliable delivery of power from point A to point B often depends on substantial construction and upgrade activities, the need for efficient project delivery has never been more critical. For manufacturers, completing pharma facility and process optimization projects quickly and cost-effectively can be challenging. As a result, many are exploring new...
The 2024 ISPE International Honor Awards were presented at the 2024 ISPE Annual Meeting & Expo in Orlando, Florida, in October. These awards provide the opportunity for the ISPE community to recognize and celebrate the dedicated professionals who volunteer countless hours to support ISPE and its mission.
This year’s 2024 ISPE Annual Meeting & Expo at Gaylord Palms in Orlando, Florida, USA was an inspiring experience, combining the energy of high-level industry discussions, networking opportunities, and moments of genuine connection. Despite the uncertainty brought on by Hurricane Milton, the conference went forward with an impressive spirit of resilience and adaptability. From insightful...
The future of manufacturing is not a battle between humans and machines. It is a collaboration that promises to redefine productivity and innovation. Industry 5.0 is poised to revolutionize how companies operate over the next decade, shifting the focus beyond mere automation and optimization to prioritizing the well-being of workers. This paradigm shift will transform workplaces, making them...
In September, ISPE released the second edition of their Good Practice Guide on Heating, Ventilation, and Air Conditioning (HVAC), which provides a detailed overview of HVAC considerations in the pharmaceutical industry. The second edition also reflects industry...
Daria Curtis works in quality assurance validation at AstraZeneca and is a member of ISPE. In this interview, conducted by Edyna Miguez, Membership Growth Manager at ISPE, Curtis shares her key areas of expertise, what prompted her to get involved with ISPE, how being a member has enhanced her professional career, and more.
In an era where advanced therapy medicinal products (ATMPs) are revolutionizing healthcare, the 2024 ISPE Pharma 4.0™ and Annex 1 Conference, taking place 10-11 December in Rome, Italy, and...
In this blog post, Rebecca Roscher – Project Manager at Bayer AG (Supply Center Grenzach) – shares how she rose from an ISPE student member to an Emerging Leader Representative, Ex-Officio, on the 2024-2025 ISPE International Board of Directors.
The ISPE Japan Affiliate held the “Young Professionals Seminar” to support the growth of recent graduates. Starting on 14 July 2023, this seminar spanned four sessions and took place at the Nihonbashi Life Science Building and Taiyo Pharma Tech Takatsuki Plant. Led by ISPE Emerging Leaders, the seminar aimed to cultivate the next generation of leaders in the pharmaceutical industry.
Governments around the world have made international commitments to reduce their environmental impact and protect nature. Policy frameworks have been established to facilitate and drive progress against agreed-upon targets. These directly impact end-to-end activities for the biopharmaceutical, pharmaceutical, and medical device sectors, including research and development, manufacturing,...
Many organizations are on the right path to sustainability, but more can still be done— especially for setting and meeting net-zero targets. Although a commitment to net-zero operations is important for all industries, it’s particularly necessary for the pharmaceutical industry, with its high energy consumption, high water demands, and the use of solvents for manufacturing.
ISPE has been honored with a 2024 APEX Award of Excellence in Writing for “ChatGPT, BARD, and Other Large Language Models Meet Regulated Pharma” by Frederick Blumenthal, Martin Heitmann, Stefan Münch, and Brandi Stockton published in the July/August 2023 issue of Pharmaceutical Engineering®.
ISPE recently announced ISPE AI®, an initiative aimed at aiding the pharmaceutical industry in realizing the potential of artificial intelligence (AI). The initiative will include a multifaceted approach to...
In each issue of Pharmaceutical Engineering®, we introduce a member of the ISPE staff who provides ISPE members with key information and services. Meet Nada Elsayed, Content Development Manager on the Publications Team.
This year, the ISPE Foundation’s Professional Development Grants program, supported by the Moderna Foundation, enabled 24 STEM students and Emerging Leaders to attend the 2024 ISPE Annual Meeting & Expo with all expenses covered.
We lost two members of the ISPE family this year, both of whom played instrumental roles in shaping the pharmaceutical industry and ISPE.
I am enthusiastic and humbled to have the opportunity to author a column on leadership for the ISPE membership. The subject of leadership has been a passion of mine since the very start of my career, 45 years ago. From the shop floor to the C-suite, I have been an ardent student of the subject.
The pharmaceutical, biotechnology, and medical device industries continue to grow as patients require more access to medicine, data that allows them to make informed decisions, and personalized care. Achieving sustainability across the supply chain while adhering to quality compliance requirements presents a challenge.
As we approach the end of another impactful year, it is a pleasure to reflect on the outstanding achievements and contributions of ISPE’s Women in Pharma community, both regionally and internationally.
As we come out of the 2024 ISPE Annual Meeting & Expo and move toward the end of the year, I find myself looking back and reflecting on what the ISPE community has accomplished over the past year.
The 2025 Mentor ISPE program promises to be a transformative year filled with growth, collaboration, and valuable learning opportunities for both mentors and mentees. As ISPE mentors and mentees embark on this journey, they’ll have the chance to build meaningful professional relationships, gain fresh insights, and strengthen skills through guided support and shared experiences. Whether ISPE...
The 2024 ISPE International Honor Awards were presented at the 2024 ISPE Annual Meeting & Expo in Orlando, Florida, in October. These awards provide the opportunity for the ISPE community to recognize and celebrate the dedicated professionals who volunteer countless hours to support ISPE and its mission. This award was presented to the family of Antonio Moreira, PhD, to posthumously...
With over 23 years industrial hands-on experience in establishing and managing quality management systems within the pre-clinical, clinical and pharmaceutical as well as medical device manufacturing industries, Mei Ping Lee, who goes by Mae, is currently the Quality Assurance Manager at Winwa Medical Sendirian Berhad, Malaysia, a pharmaceutical and complementary products manufacturer and...
The pharmaceutical industry is in the middle of a transformative shift, driven by the dual forces of Pharma 4.0™ and the updated Annex 1 guidelines. These changes are introducing innovations that not only enhance the quality and safety of sterile manufacturing but also leverage new technologies to optimize efficiency and compliance. The
Sponsored content is the sole responsibility of the authors and is not endorsed, reviewed, nor a published article of Pharmaceutical Engineering® magazine or ISPE.
Cleanroom technology is a particularly promising starting point when it comes to energy optimization. ZETA has developed an innovative method for planning cleanrooms in a process-based and energy-optimized way, and one thing is clear: simulations play a central role in this pioneering approach.
This paper focuses on the development of a diagnostic tool for predictive maintenance in industrial lyophilization systems. At the core of the system is an anomaly detection algorithm designed to identify abnormal patterns in operational data. Through its development, key diagnostic strategies have been identified to improve system reliability and early failure detection, ultimately aiming to...
Whether networking at events or collaborating through our Communities of Practice, the value of an ISPE membership is in the connections made between pharmaceutical industry professionals and Regulators to collaborate on solutions to common goals and challenges.
Are you a subject-matter expert in the global pharmaceutical industry? Are you brimming with knowledge about the latest technical developments or regulatory initiatives? Have you found an innovative solution to a real-world challenge?
Contribute your knowledge and experience to the always-evolving pharmaceutical industry!
Do you know someone whose profile or work should be featured in Pharmaceutical Engineering? Contact ISPE Publications Department.
